Hormones and Longevity: The Complete Guide to Your Body's Aging Signals
Hormones are the body's primary long-range communication system - chemical messengers that coordinate metabolism, body composition, stress response, reproduction, and tissue repair across every organ simultaneously. As we age, the hormonal milieu shifts in ways that are causally connected to the accumulation of fat, loss of muscle, cognitive decline, and metabolic deterioration. Understanding which hormonal changes matter for longevity - and which are addressable - is one of the most clinically important frontiers in aging medicine.
- Sex hormones (testosterone in men, estradiol in women) decline with age in ways that are causally connected to loss of muscle mass, increased visceral adiposity, reduced bone density, cognitive decline, and increased cardiovascular risk. These are not minor quality-of-life issues - they are longevity-relevant physiological changes.
- Testosterone replacement therapy (TRT) in men with confirmed hypogonadism significantly improves body composition, bone density, libido, mood, and insulin sensitivity. The TRAVERSE trial (2023) definitively addressed the cardiovascular safety controversy, finding no increased risk of major cardiovascular events with TRT versus placebo.
- For women, estradiol is neuroprotective, cardioprotective, and bone-protective when initiated within 10 years of menopause. The critical window hypothesis is now well-established: the timing of HRT initiation relative to menopause is the most important determinant of its risk-benefit profile.
- Growth hormone and IGF-1 decline significantly with age in a process called somatopause. While GH deficiency states are treated medically, supraphysiological GH supplementation in normal aging is not recommended - excess GH and IGF-1 signaling may promote cancer risk and is mechanistically associated with accelerated aging.
- Thyroid function, DHEA, cortisol, and melatonin all undergo age-related changes with longevity implications. Ensuring thyroid adequacy and managing chronic cortisol elevation through stress management and sleep optimization are the most actionable interventions in this category.
Endocrine aging is one of the most clinically consequential and least publicly understood aspects of longevity biology. The hormonal changes that accompany aging are not merely background noise - they are mechanistically connected to the body composition changes, metabolic deterioration, cognitive decline, and increased disease susceptibility that define the transition from middle age to old age in most adults. Understanding this landscape is essential for anyone approaching longevity medicine seriously.1
Testosterone: The Male Longevity Hormone
Total testosterone in men declines at approximately 1 to 2 percent per year after age 30, with free testosterone declining somewhat faster due to age-related increases in sex hormone binding globulin (SHBG). By age 70, the average man has approximately 35 percent lower total testosterone than at age 30. The clinical consequences of testosterone decline include loss of lean body mass, increased visceral fat, reduced bone density, insulin resistance, impaired libido and sexual function, reduced energy and motivation, and cognitive changes.2
The TRAVERSE trial (Testosterone Replacement in Men with Hypogonadism, 2023) - published in NEJM - was the definitive cardiovascular safety trial for TRT, enrolling 5,246 hypogonadal men aged 45 to 80 with high cardiovascular risk and randomizing them to testosterone gel or placebo for approximately 33 months. Primary result: no significant difference in major adverse cardiovascular events (MACE) between TRT and placebo (HR 0.96, non-inferior). This definitively resolved the cardiovascular safety controversy that had hampered clinical TRT use for a decade.3
TRT is indicated for men with confirmed hypogonadism - defined as consistently low testosterone (typically below 300 ng/dL total testosterone) combined with signs and symptoms of deficiency. Normal testosterone levels: total testosterone 400 to 900 ng/dL; free testosterone 10 to 25 pg/mL (age-adjusted). Monitoring while on TRT: hematocrit (testosterone raises RBC production; hematocrit above 54 percent warrants dose reduction), PSA, lipids, and blood pressure.
"Testosterone is not a performance enhancement drug in men who are deficient. For a hypogonadal man, restoring testosterone to normal physiological levels is equivalent to treating hypothyroidism with thyroid hormone - correcting a deficiency state."
Dr. Mohit Khera, Baylor College of Medicine, urologist and TRT researcherEstradiol: The Female Longevity Hormone
The menopause transition marks the most rapid and consequential hormonal shift in human biology - a drop from reproductive-level estradiol to near-zero within 2 to 5 years. The consequences extend far beyond hot flashes: estradiol is essential for bone remodeling (its loss triggers the most rapid bone loss in a woman's lifetime), endothelial function and cardiovascular health, myelin maintenance in the nervous system, and amyloid clearance in the brain. Estrogen deficiency is a genuine longevity risk, not merely a quality-of-life issue.4
As established in the HRT article (7.3), the key principles are: initiate within 10 years of menopause (the critical window), use transdermal estradiol rather than oral CEE (avoids hepatic first-pass and VTE risk), and use micronized progesterone rather than synthetic MPA in women with a uterus (no breast cancer signal, better cardiovascular profile). Women who had natural menopause before age 40 should receive HRT to at least age 51 (normal menopause age) to reduce excess cardiovascular, bone, and cognitive risk.
Growth Hormone and IGF-1: Somatopause
Growth hormone secretion from the pituitary declines dramatically with age - by approximately 14 percent per decade - in a process called somatopause. GH drives IGF-1 production in the liver, and IGF-1 mediates most of GH's anabolic effects on muscle and bone. Somatopause contributes to the sarcopenic body composition changes of aging - reduced lean mass, increased fat mass, reduced bone density.5
The longevity biology of GH and IGF-1 contains an important paradox: lower IGF-1 levels in adulthood are associated with longer lifespan in centenarian studies and in Mendelian randomization analyses, while GH deficiency is clearly associated with adverse body composition and metabolic effects. The resolution: physiological IGF-1 levels (appropriate to age) are associated with optimal function; supraphysiological GH supplementation in normally aging adults (without true GH deficiency) does not extend life and may promote IGF-1-dependent cancer growth. Peptides that stimulate endogenous GH secretion (sermorelin, ipamorelin, CJC-1295) are used in longevity medicine to partially restore GH pulsatility, but long-term RCT data on outcomes is limited.
Thyroid: The Metabolic Regulator
Thyroid hormones regulate the metabolic rate of virtually every cell in the body. Subclinical hypothyroidism - elevated TSH with normal T4, present in 4 to 8 percent of the adult population - is associated with elevated cardiovascular risk, cognitive slowing, fatigue, weight gain, and depression. Overt hypothyroidism is associated with substantially elevated all-cause mortality. The longevity implication: comprehensive thyroid evaluation (TSH, free T4, and in symptomatic individuals free T3) should be part of standard longevity bloodwork, and subclinical hypothyroidism in younger adults should be treated rather than monitored.
DHEA and Cortisol: The Stress Axis
DHEA-S (the stable storage form of DHEA) declines more dramatically with age than any other adrenal hormone - by 80 to 90 percent between ages 25 and 75. DHEA has both androgenic and neurosteroid effects and is associated with better physical function, reduced cardiovascular risk, and improved cognition in observational studies of older adults. Supplementation at physiological replacement doses (25 to 50 mg/day) is widely used in longevity medicine, though long-term RCT outcome data is limited. Cortisol, the primary stress hormone, tends to increase in relative terms as its DHEA counterbalance declines - chronically elevated cortisol:DHEA ratios are associated with cognitive impairment, immunosenescence, and accelerated biological aging.
References
- 1Harman SM, et al. "Longitudinal effects of aging on serum total and free testosterone levels in healthy men." Journal of Clinical Endocrinology and Metabolism. 2001;86(2):724-731. [PubMed]
- 2Bhasin S, et al. "Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical Practice Guideline." JCEM. 2018;103(5):1715-1744. [PubMed]
- 3Lincoff AM, et al. "Cardiovascular safety of testosterone-replacement therapy (TRAVERSE trial)." NEJM. 2023;389(2):107-117. [PubMed]
- 4Simpkins JW, Dykens JA. "Mitochondrial mechanisms of estrogen neuroprotection." Brain Research Reviews. 2008;57(2):421-430. [PubMed]
- 5Veldhuis JD, et al. "Somatotropic axis in the elderly." Endocrinology and Metabolism Clinics of North America. 2005;34(4):895-934. [PubMed]